Revised SPC: Praluent (alirocumab) 75 and 150 mg solution for injection in pre-filled pen

SPC updated to advise that experience of alirocumab in paediatric patients is limited to 18 patients aged 8 to 17 years with homozygous familial hypercholesterolaemia. No new safety finding was observed compared to the known adult safety profile.

electronic Medicines compendium